Glioma growth is supported by synaptic input from neurons in the brain, and particularly those at the tumor–brain interface, but it is challenging to target these inputs therapeutically without compromising healthy synaptic function. In a recent paper in Nature Biomedical Engineering, a team of scientists sought to address this problem in a mouse model of glioblastoma by locally interfering with synapses post-operatively at the site of tumor resection. Specifically, they developed and validated an injectable hydrogel to deliver a small interfering RNA against Ntrk2, which encodes the BDNF receptor TrkB — a system they call ‘HPAC–siNTRK2@Gel’.
The treatment disrupted neuron–glioblastoma synapses, reduced tumor recurrence, enhanced survival, and also potentiated the effects of chemoradiotherapy in the mouse model, without affecting behavioral function. This type of strategy may help to translate the discoveries of the cancer neuroscience field into effective treatments. Original references: Nat.
Eng. https://doi.org/10.1038/s41551-026-01757-w (2026) This is a preview of subscription content, access via your institution Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription Receive 12 print issues and online access Prices may be subject to local taxes which are calculated during checkout Nature Neuroscience https://www.nature.com/neuro/ Wiseman, S. Glioblastoma treatment gels. Nat Neurosci 29, 2381 (2026). https://doi.org/10.1038/s41593-026-02479-7 DOI: https://doi.org/10.1038/s41593-026-02479-7
Extract — continue reading at the source.
